64 evolution-"https:"-"https:"-"https:"-"https:"-"https:"-"https:"-"IFM" positions at City of Hope
Sort by
Refine Your Search
-
career development. For more information about Dr. You’s lab, please visit here. As a successful candidate, you will: Lead independent and collaborative projects investigating the molecular and cellular
-
Clinical Trials (SCT) Operations Program Manager will support the development and implementation of strategic initiatives within Clinical Trial Operations. The Operations Manager will be responsible
-
visit here . If you are passionate about some of the following things, we are working on this may be the perfect opportunity: · Development of cell-free DNA (mutation and methylation), RNA, and
-
support of leukemia genomics and other biomedical research projects. The position emphasizes next-generation sequencing (NGS) data analysis, workflow development, high-performance computing, and structured
-
Cytometry Core Director to lead a high-performance shared resource supporting basic, translational, and clinical cancer research. The Director manages daily operations, technology development, and scientific
-
collaboration with Principal Investigators and the Disease/Modality-specific Study Teams, will have primary responsibility for the clinical research content development and maintenance of all therapeutic and
-
physiology and pathogenesis. 2) Development of novel drugs to treat MASH, diabetes, and cancer. For more information on Dr. Wendong Huang’s research, please visit here . Your qualifications should include
-
Molecular Dynamics methods and experience in code development is preferred. City of Hope employees pay is based on the following criteria: work experience, qualifications, and work location. City of Hope is
-
highly motivated postdoctoral fellow to study transcriptional regulation and RNA metabolism in normal development and human diseases, such as neurological disorder, immunology, and cancer. In particular
-
: · Contribute to the development of CD38 antibody‑drug conjugates (ADCs) and other multiple myeloma targets, including monoclonal antibody (mAb) engineering, ADC conjugation, biophysical characterization (SPR